Physician profile
Robert M Han
NPI 1669714242
$4,533.47
in general payments reported to CMS, 2019-2025
31 companies · $1,872 in 2025
The $1,872 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.81 · 2020: $48.47 · 2022: $107 · 2023: $1,136 · 2024: $1,359 · 2025: $1,872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,366.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $822.90 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $501.69 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $422.09 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $399.97 | 2023-2025 | |
| Pfizer INC. | $285.49 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $267.32 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Novartis Pharmaceuticals Corporation | $264.09 | 2019-2025 | |
| Amgen INC. | $256.78 | 2022-2025 | Repatha, Evenity, Otezla |
| Vanda Pharmaceuticals INC. | $194.71 | 2024-2025 | Fanapt |
| Corcept Therapeutics | $129.15 | 2022-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.66 | 2023-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $114.63 | 2023-2025 | Caplyta |
| Exact Sciences Corporation | $96.35 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Antares Pharma, INC. | $84.45 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Merck Sharp & Dohme LLC | $76.62 | 2024 | Verquvo, Capvaxive, Vaxelis |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $70.78 | 2023-2024 | Qutenza |
| Glaxosmithkline, LLC. | $70.72 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Vertex Pharmaceuticals Incorporated | $40.03 | 2025 | |
| Xeris Pharmaceuticals, INC. | $39.72 | 2023 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $36.83 | 2024-2025 | Auvelity |
| Esperion Therapeutics, INC. | $32.12 | 2023-2025 | Nexletol |
| Scpharmaceuticals INC. | $32.03 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $31.66 | 2024-2025 | Belbuca, Xtampza |
| Dexcom, INC. | $23.95 | 2022 | |
| Amarin Pharma, INC. | $19.70 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.98 | 2025 | Eliquis |
| Alexion Pharmaceuticals, INC. | $18.78 | 2020 | |
| Aimmune Therapeutics, INC. | $17.05 | 2025 | Zenpep |
| Abbott Laboratories | $14.07 | 2023 | Freestyle Libre 2 |
| Edwards Lifesciences Corporation | $13.21 | 2020 | |
| Endogastric Solutions, INC | $12.94 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.